GHRL and obesity due to melanocortin 4 receptor deficiency: Developing drugs targeting ghrelin for obesity treatment presents a formidable challenge due to the intricate regulation of this hormone,122 the contrasting functions of acyl ghrelin and des‐acyl ghrelin in appetite and fat storage,123 the redundancy in appetite control systems,124 and significant individual variability, particularly evident in obese versus lean individuals90 among other factors.